MedElevator
Войти в исследования The Journal of hand surgery · 2025
Recurrent Treatments After Percutaneous Needle Fasciotomy for Dupuytren Contracture-A Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Matthiesen Laura Houstrup, Skov Simon Toftgaard, Lange Jeppe
Аннотация
PURPOSE: The purpose of this study was to estimate the risk of recurrent treatment after percutaneous needle fasciotomy (PNF) for Dupuytren contracture, defined as any subsequent treatment in a previously PNF-treated finger.
METHODS: This is a registry-based follow-up study on PNF-treated patients at Silkeborg Regional Hospital between 2007 and 2015. The first PNF procedure within the study period was defined as the index procedure. Succeeding data relative to the PNF index procedure were extracted at a national level by the Danish National Patient Registry and the Danish Civil Registration System in 2018 to identify all possible recurrent treatments. The registries lack information about which specific hand and finger were treated. A review of medical records was performed to validate whether it was a recurrent treatment of the PNF index procedure. As access to medical records was limited to Silkeborg Regional Hospital, data validation was only feasible for patients treated in Silkeborg during the follow-up period (subcohort X). To compensate for the lack of complete data validation, we estimated the best- and worst-case scenarios of recurrent treatments in the total cohort.
RESULTS: A total of 2,257 unique patients (3,331 PNF-treated fingers) were identified. Of those, 1,724 (76%) patients (2,511 [75%] fingers) were included in subcohort X. In subcohort X, 28% had received a recurrent treatment at a median follow-up time of 6.8 (interquartile range [IQR], 4.6-9.3; min-max, 1.0-11.7) years. In the total cohort, recurrent treatments were estimated to be between 21% and 46% at a median follow-up time of 7.2 (IQR, 4.9-9.5; min-max, 1.0-11.7) years.
CONCLUSIONS: This study provides information about recurrent treatments after PNF in a large Scandinavian cohort, which was estimated to be between 21% and 46% at a median follow-up time of 7.2 (IQR, 4.9-9.5; min-max, 1.0-11.7) years.
TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic IV.
METHODS: This is a registry-based follow-up study on PNF-treated patients at Silkeborg Regional Hospital between 2007 and 2015. The first PNF procedure within the study period was defined as the index procedure. Succeeding data relative to the PNF index procedure were extracted at a national level by the Danish National Patient Registry and the Danish Civil Registration System in 2018 to identify all possible recurrent treatments. The registries lack information about which specific hand and finger were treated. A review of medical records was performed to validate whether it was a recurrent treatment of the PNF index procedure. As access to medical records was limited to Silkeborg Regional Hospital, data validation was only feasible for patients treated in Silkeborg during the follow-up period (subcohort X). To compensate for the lack of complete data validation, we estimated the best- and worst-case scenarios of recurrent treatments in the total cohort.
RESULTS: A total of 2,257 unique patients (3,331 PNF-treated fingers) were identified. Of those, 1,724 (76%) patients (2,511 [75%] fingers) were included in subcohort X. In subcohort X, 28% had received a recurrent treatment at a median follow-up time of 6.8 (interquartile range [IQR], 4.6-9.3; min-max, 1.0-11.7) years. In the total cohort, recurrent treatments were estimated to be between 21% and 46% at a median follow-up time of 7.2 (IQR, 4.9-9.5; min-max, 1.0-11.7) years.
CONCLUSIONS: This study provides information about recurrent treatments after PNF in a large Scandinavian cohort, which was estimated to be between 21% and 46% at a median follow-up time of 7.2 (IQR, 4.9-9.5; min-max, 1.0-11.7) years.
TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic IV.